Donor-derived T lymphocyte that responds to tumor antigens emerges after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in association with the status of immune recovery. To analyze the frequency of specific T lymphocyte against tumor antigens, such as PR1, PRAME and WT1, after alloHSCT, a tetramer-based analysis was performed in 97 samples taken from 35 patients (9 AML, 11 MDS, 2 CML, 4 ALL, 7 lymphoma and 2 renal cell carcinoma [RCC]) with the HLA-A02 phenotype. Regarding WT1, positive results were detected in 39 of 97 samples and 7 (2 CML, 1 ALL, 2 lymphoma and 2 RCC) patients, which frequency was higher than PR1 and PRAME. On the basis of those results, we performed serial analyses of WT1 specific lymphocyte during the clinical course in 2 patients with RCC who underwent alloHSCT, to examine the precise correlation between the kinetics of WT1 specific T lymphocyte, the occurrence of GVHD and the observed clinical response. A higher positive rate for WT1 specific T lymphocyte and a correlation with GVHD and the clinical response was detected. Those results might suggest the contribution of WT1 specific T lymphocyte on the antitumor effect after alloHSCT.
View full abstract